By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galectin Therapeutics 

7 Wells Avenue, Suite #34

Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


Company News
Galectin Therapeutics To Webcast Corporate Update Following Annual Meeting Of Stockholders 5/15/2015 10:16:56 AM
Galectin Therapeutics Reports No Drug-Drug Interaction Between GR-MD-02 And Midazolam 5/14/2015 1:30:17 PM
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase II Nash Program 5/11/2015 7:46:01 AM
Galectin Therapeutics Presented Research With GR-MD-02 At The American Association for Study of Liver Diseases Industry Colloquium 3/24/2015 10:24:19 AM
Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update 3/19/2015 7:56:17 AM
Galectin Therapeutics Engages PPD, Inc. (PPDI) To Conduct GR-MD-02 Phase 2 Trial In NASH, Submits Special Protocol Assessment To FDA 3/12/2015 7:17:30 AM
Galectin Therapeutics To Present At The 27th Annual ROTH Conference 3/3/2015 8:23:04 AM
Galectin Therapeutics Announces Details Of The Design Of Its Phase 2 Program With GR-MD-02 2/24/2015 7:16:56 AM
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 Is Safe With Potential For Therapeutic Effect On Fibrosis In NASH Patients With Advanced Fibrosis 1/7/2015 7:22:17 AM
Galectin Therapeutics To Present At 7th Annual LD Micro Main Event Conference 12/4/2014 3:48:48 PM